Diagnosis of Pneumocystis pneumonia: Evaluation of four serologic biomarkers

F. Esteves, S. S. Calé, R. Badura, M. G. de Boer, F. Maltez, E. J. Calderón, T. J. van der Reijden, E. Márquez-Martín, F. Antunes, O. Matos

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


The diagnosis of Pneumocystis pneumonia (PCP) relies on microscopic visualization of Pneumocystis jirovecii organisms or DNA detection in pulmonary specimens. This study aimed to assess the usefulness of (1-3)-β- d-glucan (BG), Krebs von den Lungen-6 antigen (KL-6), lactate dehydrogenase (LDH) and S-adenosyl methionine (SAM) as serologic biomarkers in the diagnosis of PCP. Serum levels of BG, KL-6, LDH and SAM were investigated in 145 Portuguese patients, 50 patients from the Netherlands, 25 Spanish patients and 40 Portuguese blood donors. Data on clinical presentation, chest imaging and gasometry tests were available. PCP cases were confirmed by microscopy and PCR techniques. A cost-effectiveness analysis was performed. BG was found to be the most reliable serologic biomarker for PCP diagnosis, followed by KL-6, LDH and SAM. The BG/KL-6 combination test was the most accurate serologic approach for PCP diagnosis, with 94.3% sensitivity and 89.6% specificity. Although less sensitive/specific than the reference standard classic methods based on bronchoalveolar lavage followed by microscopic or molecular detection of P.jirovecii organisms, the BG/KL-6 test may provide a less onerous procedure for PCP diagnosis, as it uses a minimally invasive and inexpensive specimen (blood), which may be also a major benefit for the patient's care. The BG/KL-6 combination test should be interpreted within the clinical context, and it may be used as a preliminary screening test in patients with primary suspicion of PCP, or as an alternative diagnostic procedure in patients with respiratory failure or in children, avoiding the associated risk of complications by the use of bronchoscopy.

Original languageEnglish
Pages (from-to)379.e1-379.e10
JournalClinical Microbiology And Infection
Issue number4
Publication statusPublished - 1 Apr 2015


  • Diagnosis
  • Immunocompromised patients
  • Pneumocystis jirovecii
  • Pneumonia
  • Serologic biomarkers

UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-Being


Dive into the research topics of 'Diagnosis of Pneumocystis pneumonia: Evaluation of four serologic biomarkers'. Together they form a unique fingerprint.

Cite this